PUBLISHER: DataM Intelligence | PRODUCT CODE: 1133512
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1133512
Organ Preservation Market size was valued at US$ 233.29 million in 2021 and is estimated to reach US$ 417.41 million by 2029, growing at a CAGR of 5.86% during the forecast period (2022-2029).
The organ transplantation involves an organ removal from a donor body, transporting the organ, and transplanting into another body, all while preserving the organ without significant damage. Creating hypothermia by reducing the organ temperature may help preservation, but different body organs need precise and appropriate storage environments to maintain their anatomical and physiological processes.
The major driving forces are the rising incidence of organ failures, increase in research and development, technological advancements and rising chronic kidney disease are expected to drive market growth.
The rising incidences of multiple organ failures is expected to drive the market growth
The global market for organ preservation market is primarily driven by the rising cases of multiple organ failure. The increasing number of solid-organ transplantation procedures coupled with an aging population are expected to promote market growth.
Increase in cases of chronic kidney diseases leads to increase in kidney transplants worldwide. Earlier a recipient can receive kidney only from the same blood group which led to delay in finding a proper donor. Delay in transplant was responsible for increased mortality. Kidney transplant is the most desired and cost-effective modality of renal replacement therapy for patients with irreversible chronic kidney failure. According to National Institute of Health (NIH), chronic kidney disease, has a high global prevalence with a consistent estimated global prevalence of between 11 to 13% with the majority stage 3.
Other factors such as the growing government and NGO initiatives to encourage organ donation along with the increasing awareness of organ donations assist the market development. Technological advancements, for example, the normothermic machine perfusion which is a new paradigm for organ preservation also contribute to market growth.
The high cost associated with the organ transplantation will hamper the growth of the market
However, the high cost of organ transplantation, a significant gap between the number of organs donated and organs required annually, and limited medical reimbursements for organ donation and transplantation may hinder the market progress.
The static cold storage segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
The static cold storage (SCS) segment is the highest market share holder in the global organ preservation market, owing to the increased number of incidences od organ failutes leading to growing organ transplantation and research activities. Transition of secured organs of donor on ice is involved in static cold storage. It has been the best standard for the preservation of multiple orgns for many decades. Static cold storage depends on hypothermia by which it minimizes the demand of oxygen as well as cellular metabolism and get to extend the time of preservation of organs. During cold storage, organ's metabolic activity gets reduced around 10 times and increases anaerobic metabolism that stops the energy cycle. According to nature journal publication titled "Organ preservation: from past to future", The static cold storage is the most effective and simple way for preservation and transportation of the organs. This is the most common method used for the preservation of organs.
North America region holds the largest market share of the global organ preservation market
North America dominates the global organ preservation market, and it is primarily attributed to the rising geriatric population leading to the higher occurrence of organ failures. The growing prevalence of cardiovascular diseases and the increasing cases of kidney failure are likely to enhance the growth of organ preservation. Furthermore, factors such as high spending of GDP in healthcare, growing government initiatives, and reimbursement policies in advanced medical treatment options are likely to enhance the growth of the organ preservation market in the region.
According to a report by the National Chronic Kidney Disease report 2021, chronic kidney disease causes more deaths than breast cancer or prostate cancer in the region. It is the under-recognized public health crisis. It affects an estimated 37 million people in the U.S. that is equivalent to 15% of the adult population or more than one in seven adults. The high prevalence of obesity, hypertension and diabetes are some of the reasons that are causing chronic kidney disease. Kidney transplant is considered the best treatment option for people facing kidney failure because it can increase the chances of living a longer, healthier life.
Moreover, the extensive research activities are undertaken by a majority of prominent players in the area, and rising demand for technologically advanced treatment will propel the market.
The organ preservation market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Xvivo Perfusion AB, CryoLife, Inc., Lifeline Scientific, BioTime, Inc., Claris Lifesciences Limited, BioLife Solutions, Inc., Dr. Franz Kohler Chemie GmbH, Bristol-Myers Squibb, Tolerotech, Inc. and 21st Century Medicine.
Key players are adopting strategies such as mergers and acquisitions, partnerships, and regional expansion to stand out as strong competitors in the market. New product launches along with an increased focus on R&D are other ways the leading players improve their market presence. For instance, in Oct 2021, Xvivo, medical technology company announced its acquisition of STAR teams, a specialized AI-adapted transplant recovery. They work on combined data-driven approach.
In Aug 2021, BioLife Solution, developer and provider of cell therapies or gene therapies products and therapies announced its acquisition of Sexton Biotechnologies Inc.
Xvivo is a company of medical technology that develops better solutions for organ, cell and tissue preservation or perfusion that can be used for transplantation. It was established in 1998 and is headquartered in Gothenburg, Sweden. It operates in three different segments: durable goods, non-durable goods and services.
PERFADEX Plus: It is a dextran-based electrolyte, extracellular with low potassium preservation solution for perfusion, rapid cooling and cold static storage of lungs of donor. It is already supplemented with THAM and calcium ions hence easy and ready to use.
Key Developments: In Sep 2022, Xvivo announced that United States Food and Drug Administration granted its liver assist device used for preserving the livers of donor before transplantation via ex-vivo oxygenated machine perfusion with breakthrough device designation.
The global organ preservation market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.
LIST NOT EXHAUSTIVE